3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with ziprasidone in 1 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (ziprasidone) | Trials (ziprasidone) | Recent Studies (post-2010) (ziprasidone) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 1,068 | 254 | 362 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | ziprasidone (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.005 | |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | 5.39 | |
| D | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0004 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2301 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D | 1 |
1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and ziprasidone
| Article | Year |
|---|---|
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Neostriatum; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Single-Blind Method; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2005 |